Advertisement


Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

AACR Annual Meeting 2021

Advertisement

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.



Related Videos

Lung Cancer
Immunotherapy

Patrick M. Forde, MD, on NSCLC: Nivolumab and Chemotherapy as Neoadjuvant Treatment

Patrick M. Forde, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses results from the CheckMate 816 trial, which showed that adding nivolumab to chemotherapy as a neoadjuvant treatment for patients with resectable non–small cell lung cancer improved the pathologic complete response rate to 24%, compared to 2.2% with chemotherapy alone (Abstract CT003).

Immunotherapy

Michel Sadelain, MD, PhD, on the Road to Synthetic Immunity: Novel CAR Designs

Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the challenges in developing CAR T-cell therapy, as well as the progress being made, such as creating hybrid CAR and T-cell receptors that should enable T cells to recognize much lower levels of antigens. The field, he says, is poised to take on a range of solid tumors to extend the successes in hematologic malignancies.

Immunotherapy
Pancreatic Cancer

Katelyn T. Byrne, PhD, on the Clinical Impact of T-Cell Inflammation in the Tumor Microenvironment

Katelyn T. Byrne, PhD, of the Perelman School of Medicine at the University of Pennsylvania, discusses the first in-depth analysis of the impact of selicrelumab, an anti-CD40 antibody, which was found to enrich T cells in pancreatic tumors, activate the immune system, and alter the tumor stroma (Abstract CT005).

Issues in Oncology

Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities

Ralph R. Weichselbaum, MD, of the University of Chicago, discusses oligometastasis as a part of the metastatic spectrum where ablative therapies, such as surgery or stereotactic body radiotherapy, may be curative alone or with systemic agents, as well as some potential biomarkers to guide treatment selection.

Lymphoma

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CHRONOS-3 trial, which showed that copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (Abstract CT001).

Advertisement

Advertisement



Advertisement